Tina Hesman Saey

Tina Hesman Saey

Senior Writer, Molecular Biology

Senior writer Tina Hesman Saey is a geneticist-turned-science writer who covers all things microscopic and a few too big to be viewed under a microscope. She is an honors graduate of the University of Nebraska-Lincoln where she did research on tobacco plants and ethanol-producing bacteria. She spent a year as a Fulbright scholar at the Georg-August University in Göttingen, Germany, studying microbiology and traveling.  Her work on how yeast turn on and off one gene earned her a Ph.D. in molecular genetics at Washington University in St. Louis. Tina then rounded out her degree collection with a master’s in science journalism from Boston University. She interned at the Dallas Morning News and Science News before returning to St. Louis to cover biotechnology, genetics and medical science for the St. Louis Post-Dispatch. After a seven year stint as a newspaper reporter, she returned to Science News. Her work has been honored by the Endocrine Society, the Genetics Society of America and by journalism organizations.

All Stories by Tina Hesman Saey

  1. collage of people wearing different masks
    Health & Medicine

    Making masks fit better can reduce coronavirus exposure by 96 percent

    Double masking, rubber bands and other hacks can produce a tighter fit and prevent aerosol particles that can carry coronavirus from getting through.

  2. Sara Berech draws a dose of Johnson & Johnson’s vaccine
    Health & Medicine

    One-shot COVID-19 vaccine is effective against severe disease

    The effectiveness of Johnson & Johnson’s vaccine at preventing hospitalization and death holds up against a South Africa variant of the coronavirus.

  3. Novavax headquarters sign
    Health & Medicine

    Novavax’s COVID-19 vaccine is effective, but less so with some variants

    Novavax’s vaccine fends off the original coronavirus and a U.K. variant, but had more trouble with a South Africa variant.

  4. twin girls

    Some identical twins don’t have identical DNA

    Mutations arising early in development may account for genetic differences between identical twins.

  5. people getting vaccinated
    Health & Medicine

    The FDA has authorized Pfizer’s COVID-19 vaccine. Now what?

    It’s the first to win emergency use approval in the United States.

  6. bottle of Pfizer-BioNTech’s COVID-19 vaccine
    Health & Medicine

    Experts recommend the FDA approve Pfizer’s COVID-19 vaccine for emergency use

    Pfizer-BioNTech’s COVID-19 vaccine is one step closer to emergency use authorization in the United States.

  7. Pfizer headquarters in New York City
    Health & Medicine

    Here’s what you need to know about the COVID-19 vaccines

    There are still important unknowns about how Pfizer’s vaccine and others will work once they get injected in people around the world.

  8. cold case for vaccine storage
    Health & Medicine

    The ‘last mile’ for COVID-19 vaccines could be the biggest challenge yet

    The need for cold storage and booster shots could create problems for distributing coronavirus vaccines to nearly everyone in the world.

  9. line of shoppers outside Selfridges department store
    Health & Medicine

    The U.K. is the first country to authorize a fully tested COVID-19 vaccine

    Pfizer will deliver the first of 40 million doses of its coronavirus vaccine promised to the United Kingdom in the coming days.

  10. adenovirus illustration
    Health & Medicine

    Oxford and AstraZeneca say their COVID-19 vaccine works too

    A third major vaccine, which may be easier to distribute than others, appears to prevent disease and maybe transmission of the coronavirus.

  11. Freezers at a Pfizer facility
    Health & Medicine

    Here’s why COVID-19 vaccines like Pfizer’s need to be kept so cold

    Both Pfizer and Moderna built their vaccines on RNA. Freezing them keeps their fragile components from breaking down.

  12. photo of a syringe with the Pfizer and BioNTech logos in the background
    Health & Medicine

    New Pfizer results show its COVID-19 vaccine is nearly 95% effective

    With final results – including showing its vaccine is 94 percent effective in the elderly – Pfizer is poised to request emergency use authorization.